Qyuns Therapeutics Co., Ltd. (China)

Homepage: qyuns.net

Alternate names: Jiangsu Qyuns Therapeutics Co., Ltd., Qyuns, Qyuns Therapeutics, Qyuns Therapeutics Co., Ltd.

ROR: 003q00x35

OpenAlex ID: I4405266863

A Biosimilarity Study Between QX001S and Ustekinumab in Healthy Chinese Male Subjects

2021 · Lei Gao, Qingmei Li, et al. · Frontiers in Pharmacology · 9

A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra ® ) in Chinese healthy subjects

2021 · Hong Zhang, Xiaojiao Li, et al. · Annals of Medicine · 9

Previously Unrecognized Nonreproducible Antibody–Probe Interactions

2022 · Jiaojiao Pan, Lan Yang, et al. · Analytical Chemistry · 6

Development of a novel humanized anti-TSLP monoclonal antibody, QX008N, and exploration of combination therapy of anti-TSLP antibody and anti-IL-4R antibody

2024 · Xiaomu Wang, Yong Kong, et al. · International Immunopharmacology · 5

Structural basis for the recognition of IFNAR1 by the humanized therapeutic monoclonal antibody QX006N for the treatment of systemic lupus erythematosus

2024 · Xiaorong Chen, Huimin Ke, et al. · International Journal of Biological Macromolecules · 5

Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of the QX002N anti-IL-17 Monoclonal Antibody: A Phase I, Randomized, Double-Blind, Single Ascending Dose Study in Healthy Chinese Volunteers

2022 · Min Wu, Hong Zhang, et al. · Frontiers in Pharmacology · 5

Safety and Efficacy of Anti–IL-23 Monoclonal Antibody QX004N for Patients With Psoriasis: A Randomized Clinical Trial

2024 · Xiaojiao Li, Bing Li, et al. · JAMA Dermatology · 4

Pharmacokinetics, Safety, and Immunogenicity of Intravenous and Subcutaneous Single-Dose QX002N Injection in Healthy Subjects: A Randomized, Open, Parallel, Single-Center, Phase I Study

2024 · Zhen-Wei Shen, Kai-Qi Wu, et al. · Rheumatology and Therapy · 2

[Preparation of mouse monoclonal antibody against human B7-1 (CD80) and its inhibitory effect on tumor cells in vitro].

2018 · Tianming Yan, Yuyu Wang, et al. · PubMed · 1

Structural basis of QX007N neutralizing interleukin-33 for asthma and COPD treatment

2026 · Qi Wang, Huimin Ke, et al. · Structure

HS-20137 for Chinese Moderate-to-Severe Psoriasis: A Randomized, Double-Blinded, Phase 2 Study

2026 · Lin Cai, Xiaohua Wang, et al. · Dermatology and Therapy

QX 008 N , an Anti‐ TSLP Monoclonal Antibody: Pharmacokinetics, Tolerability, and Immunogenicity in Healthy Chinese Subjects

2026 · Zhen‐Wei Shen, Qi Jiang, et al. · Clinical and Translational Science

Safety, pharmacokinetics, preliminary efficacy, pharmacodynamics, and immunogenicity of QX002N, an anti-IL-17A monoclonal antibody, after short-term treatment of active ankylosing spondylitis

2025 · Min Wu, Qianqian Li, et al. · BMC Pharmacology and Toxicology

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers

2023 · Xiaojiao Li, Bing Li, et al. · BioDrugs

Generation and characterization of a humanized anti-IL-17A rabbit monoclonal antibody

2021 · Wei Chen, Yong Kong, et al. · Protein Expression and Purification

Works count: 15

Citation count: 96